🔗 Share this article

An underground market for unlicensed slimming drugs is propelled by social media fitness personalities and vendors on communication apps, based on new investigations.

Experimental Treatment Acquiring Popularity Online

The experimental drug, which is still in research studies, is being advertised by online personalities for its alleged weight-reducing properties. Followers are encouraged to contact these profiles directly for source information, while also receiving promotional offers.

Thriving Commerce on Messaging Platforms

Separately, a flourishing market exists on messaging services, where communities with numerous of participants share “before and after” images, administration instructions and assertions of rapid UK delivery. Vendors promote the substance there before directing buyers to WhatsApp for transactions.

Understanding Retatrutide

Retatrutide is an investigational injectable developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials suggest it could assist patients lose up to a quarter of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the next Ozempic.

Healthcare Experts Express Concerns

However, doctors and pharmacists have warned that the distribution of what remains an unlicensed drug in the United Kingdom is a cause for concern and could lead to individuals injecting substances of uncertain source.

Some experts stated the demand for the experimental drug could be linked to the increasing cost of approved weight loss products such as Mounjaro.

Regulatory Position and Implementation

Selling the unapproved drug on social media or messaging apps is illegal in the UK, as it is an unapproved medication that cannot be promoted or supplied for personal consumption under the British medical regulations.

Some influencers attempt to sidestep the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and distribution can still violate medicines, advertising, and consumer laws, potentially leading to fines, prosecution or imprisonment.

Service Response and Content Removal

Based on the social media company, the platform has removed problematic material and prohibited related keywords and search suggestions. The company said it was committed to maintaining the service safe and allocating resources in strengthening compliance measures.

Digital Marketplace Operations

Research also discovered communities with up to 9,000 participants selling the experimental drug using the platform's integrated search feature, which operates like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, filled with photos of weight loss, positive reviews and step-by-step instructions for mixing or injecting at residence.

After minutes of joining one community, a seller shared contact information, where the majority of purchases occur. The vendor sent an guidebook and promised delivery within two days. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one inquired about body mass, health issues or past usage.

Item Information and Pricing

Inside these communities, posts display dark colored packages with Royal Mail labels, stating to contain new batches. One message read: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at residence with sterile water, or ready-to-use pens typically sold at £160 for 20mg. When asked how much time a pen should last, sellers give conflicting answers ranging from a few weeks to “depends on your body”.

Platform Oversight and Safety Measures

A representative for the messaging service said it actively moderated harmful content on its platform including content that promoted the “misuse of controlled medications”. The organization noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are administering substances they can’t verify. Even if the research behind retatrutide is sound, these online versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at Chemist4U.

A medical professional of Asda Online Doctor connected the surge in interest to recent price rises for authorized weight-loss drugs such as Mounjaro. “With prices increasing, patients are using social media. But fake injections are highly dangerous. You cannot know what’s inside or whether the conditions they were produced in was clean,” she explained.

Her staff has previously seen patients injured by self-injection from unverified suppliers. “We understand the disappointment, but buying from messaging apps or WhatsApp is gambling with your health,” said the doctor. “These materials could be contaminated or improperly measured.”

Manufacturer Position

A spokesperson from the pharmaceutical company stated the substance was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for human use,” they explained, noting that any item “misleadingly claiming itself as a company experimental product not yet authorized … may expose patients to possibly significant health risks”.